RZLT (Rezolute) Short-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Rezolute Short-Term Debt?

Rezolute's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

Rezolute Short-Term Debt Historical Data

The historical data trend for Rezolute's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rezolute Short-Term Debt Chart

Rezolute Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Short-Term Debt

Get a 7-Day Free Trial

Rezolute Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Rezolute Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Rezolute Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Rezolute's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Rezolute Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065

Website

https://www.rezolutebio.com

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Executives

Wladimir Hogenhuis	director	60 LEVERONI COURT, NOVATO CA 94949
Brian Kenneth Roberts	officer: Chief Medical Officer	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Young-jin Kim	director	49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Nevan C Elam	director, 10 percent owner, officer: Chief Executive Officer	C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Handok, Inc.	10 percent owner	132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Gil M Labrucherie	director	150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Nerissa Kreher	director	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Philippe Fauchet	director	C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim	director	C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc.	10 percent owner	700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller	officer: VP Finance & CAO	C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young Chul Sung	director	101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola	officer: Chief Financial Officer	111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp	10 percent owner	2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch	director	C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089